arrow
M

Markella V. Zanni

massachusetts general hospital and harvard medical school
H指数:35
被引数:4,979

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis

REPRIEVE研究人群中的高血压患病率及控制情况:一项二次分析的结果

2026-08-200
OAAI
Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial

艾滋病病毒感染者中高血压的患病率、危险因素及对心血管系统的影响:REPRIEVE试验的二次分析

2026-04-290
PRE
Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis

匹伐他汀对血脂的影响与主要不良心血管事件的关系:一项REPRIEVE次要分析

2026-04-020
OAAI
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE

转换为整合酶抑制剂后的肥胖、糖尿病、高血压和主要不良心血管事件风险:一项基于REPRIEVE试验的靶向试验模拟研究

2026-03-270
PRE
Visceral adipose tissue and liver fat on 17-beta estradiol-dominant gender-affirming hormone therapy: A US-based cohort
2026-01-010
OA
Statin Effects on Pericoronary Adipose Tissue Density in People With HIV

他汀类药物对HIV感染者冠状动脉周围脂肪组织密度的影响

2025-12-010
OAAI
Spectrum From Acute Myocardial Injury to Infarction Among People With Human Immunodeficiency Virus Seeking Emergency Care in the United States: Presentations, Provider Responses, and Clinical Outcomes

从急性心肌损伤到心肌梗死:美国寻求急诊治疗的人类免疫缺陷病毒感染者的人群谱系、临床表现、医疗反应及临床结局

2025-12-010
OAAI
Statin-dependent and-independent pathways are associated with major adverse cardiovascular events in people with HIV

他汀依赖性和非依赖性通路与HIV感染者中的主要不良心血管事件相关。

2025-11-170
OAAI
Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2

基于PCE、PREVENT和SCORE2对全球HIV感染者心血管疾病预防队列的风险评估

2025-11-011
OAAI
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis

抗逆转录病毒药物对REPRIEVE试验中主要不良心血管事件的影响:一项纵向队列分析

2025-06-040
PRE
Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial

匹他伐他汀对HIV感染者表观遗传衰老生物标志物的影响:REPRIEVE试验的试点亚组研究

2025-06-013
PRE
Factors Affecting Risk of Cardiovascular Disease (CVD) Events in a Global CVD Prevention Cohort of People With Human Immunodeficiency Virus (HIV)

影响人类免疫缺陷病毒(HIV)感染者全球心血管疾病(CVD)预防队列中心血管事件风险的因素

2025-04-250
PRE
Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort
2025-04-010
OAAI
Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial
2024-12-110
PRE